Key Highlights

  • Revenue was US$15,797 million, down 1% at constant currency.
  • Pre-tax impairments of US$7.1 billion, mainly relating to CSL Vifor, produced a statutory net loss of US$2,579 million.
  • Underlying NPAT was US$2,837 million, down 3% at constant currency.
  • Underlying NPATA Earnings Per Share were US$6.43, compared with US$6.65 in FY25.

Why did CSL Limited (ASX:CSL) report a statutory net loss of US$2,579 million for FY26 when its underlying earnings were broadly steady? The answer, in results released on 18 August 2026 for the year to 30 June 2026, is a large set of non-cash impairments and restructuring costs. CSL booked pre-tax impairments of US$7.1 billion, mainly relating to its CSL Vifor business, plus about US$0.8 billion of one-off restructuring costs, while underlying net profit after tax was US$2,837 million. The result is described by the company's Leadership and commentators as a reset year, and the FY27 guidance sets out what a recovery would need to look like.

What CSL does

CSL is a global biotechnology company with three main businesses. CSL Behring is the largest and produces plasma-derived therapies, including immunoglobulins and albumin, as well as recombinant products. CSL Vifor focuses on iron deficiency, nephrology and related areas. CSL Seqirus is a major influenza Vaccine provider. Revenue is reported in US dollars even though the company is listed in Australia, so exchange rates matter for Australian-dollar investors.

Plasma margins are sensitive to donor collection costs and yields, while vaccines depend on seasonal demand.

FY26 results: reported figures

From CSL's 18 August 2026 ASX announcement (US dollars, reported unless stated):

Revenue of A$15,797 million, down 1% at constant currency.

NPATA (net profit after tax before Amortisation of acquired intangibles) of A$3,098 million, down 2% at constant currency.

Underlying NPAT of A$2,837 million, down 3% at constant currency.

Underlying NPATA earnings per share of A$6.43, compared with A$6.65 in FY25.

A reported NPAT loss of A$2,579 million, compared with a profit of A$3,002 million in FY25.

A full-year Dividend of A$2.92 per share, maintained at the FY25 level.

Pre-tax impairments totalled A$7.1 billion, with A$1.6 billion in the first half and A$5.5 billion in the second half, mainly Goodwill and intangibles at CSL Vifor, plus impairments relating to Seqirus self-amplifying mRNA intellectual property and plant and equipment. Net of tax and attributable to CSL, the impairments and restructuring costs were about A$5.4 billion, which drives the statutory loss.

Why the impairments matter

Impairments are non-cash write-downs that recognise an asset is worth less than previously recorded. The Vifor charge implies that the expected future cash flows from that Acquisition are lower than assumed when it was bought. That is a signal about how the company views the business's prospects. The company also expects a Vifor revenue decline of about 25% in FY27 (see below), which is consistent with that write-down, although the announcement as reviewed did not link the two explicitly.

But impairments also suggest past acquisitions did not deliver expected returns.

Leadership and strategy

The announcement states that Gordon Naylor is interim CEO and managing director, appointed to accelerate CSL's strategic transformation, and that Ken Lim is chief financial officer.

FY27 guidance

At FY26 exchange rates, CSL guided to:

CSL Behring revenue growth in the mid-single digits.

CSL Vifor revenue decline of about 25%.

CSL Seqirus revenue growth in the low single digits.

A foreign exchange headwind of about A$50 million, impairments of about A$200 million, Capital Expenditure of about A$1 billion (plus or minus A$100 million), and an A$1.1 billion share buyback.

The pattern is a bigger Behring contribution and a smaller Vifor, with flat revenue but growing profit, which implies Margin improvement. Guidance is a company target, not a result.

Competitive and sector position

In plasma, CSL competes with Takeda, Grifols and others, and has historically been a scale leader. In vaccines, it competes with Sanofi, GSK and other influenza vaccine suppliers. The Vifor Franchise competes in nephrology and iron therapies, where the 25% FY27 revenue decline guided for the Business suggests substantial competitive or pricing pressure, although the cause was not stated in the material reviewed.

What to watch

Upcoming developments include the first-half FY27 result, due in February 2027 on CSL's usual timetable; the appointment of a permanent CEO; progress on the A$1.1 billion buyback; Behring growth against the mid-single-digit guide; the Vifor decline; and updates on Seqirus strategy.